246 related articles for article (PubMed ID: 25779099)
1. The impact of companion diagnostic device measurement performance on clinical validation of personalized medicine.
Li M; Yu T; Hu YF
Stat Med; 2015 Jun; 34(14):2222-34. PubMed ID: 25779099
[TBL] [Abstract][Full Text] [Related]
2. Impact of Biomarkers on Personalized Medicine.
Carrigan P; Krahn T
Handb Exp Pharmacol; 2016; 232():285-311. PubMed ID: 26330258
[TBL] [Abstract][Full Text] [Related]
3. Statistical consideration and challenges in bridging study of personalized medicine.
Li M
J Biopharm Stat; 2015; 25(3):397-407. PubMed ID: 24897254
[TBL] [Abstract][Full Text] [Related]
4. [The relevance of biomarkers for personalised medicine].
Großhennig A; Benda N; Koch A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1480-8. PubMed ID: 24084852
[TBL] [Abstract][Full Text] [Related]
5. Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials.
Van Heertum RL; Scarimbolo R; Ford R; Berdougo E; O'Neal M
Drug Des Devel Ther; 2015; 9():5215-23. PubMed ID: 26392755
[TBL] [Abstract][Full Text] [Related]
6. Personalized Cardiovascular Medicine Today: A Food and Drug Administration/Center for Drug Evaluation and Research Perspective.
Blaus A; Madabushi R; Pacanowski M; Rose M; Schuck RN; Stockbridge N; Temple R; Unger EF
Circulation; 2015 Oct; 132(15):1425-32. PubMed ID: 26459078
[TBL] [Abstract][Full Text] [Related]
7. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
8. An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine.
Nasser S; Kurdolgu AA; Izatt T; Aldrich J; Russell ML; Christoforides A; Tembe W; Keifer JA; Corneveaux JJ; Byron SA; Forman KM; Zuccaro C; Keats JJ; Lorusso PM; Carpten JD; Trent JM; Craig DW
Pac Symp Biocomput; 2015; ():56-67. PubMed ID: 25592568
[TBL] [Abstract][Full Text] [Related]
9. ENVIRONMENTAL SCAN ON PHARMACEUTICALS REQUIRING COMPANION DIAGNOSTICS.
Cowling T; Boucher M
Int J Technol Assess Health Care; 2016 Jan; 32(5):327-336. PubMed ID: 27955717
[TBL] [Abstract][Full Text] [Related]
10. An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
Do K; O'Sullivan Coyne G; Chen AP
Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
12. Companion diagnostic testing for targeted cancer therapies: an overview.
Fan YS
Genet Test Mol Biomarkers; 2013 Jul; 17(7):515-23. PubMed ID: 23574530
[TBL] [Abstract][Full Text] [Related]
13. Personalized health care beyond oncology: new indications for immunoassay-based companion diagnostics.
Batrla R; Jordan BW
Ann N Y Acad Sci; 2015 Jun; 1346(1):71-80. PubMed ID: 25866164
[TBL] [Abstract][Full Text] [Related]
14. The impact of new trends in POCTs for companion diagnostics, non-invasive testing and molecular diagnostics.
Huckle D
Expert Rev Mol Diagn; 2015 Jun; 15(6):815-27. PubMed ID: 25990929
[TBL] [Abstract][Full Text] [Related]
15. Statistical evaluation of drug efficacy for bridging study in companion diagnostic test trials.
Bu Y; Zhou XH
J Biopharm Stat; 2016; 26(6):1118-1124. PubMed ID: 27649095
[TBL] [Abstract][Full Text] [Related]
16. Challenges in the clinical implementation of precision medicine companion diagnostics.
Keeling P; Clark J; Finucane S
Expert Rev Mol Diagn; 2020 Jun; 20(6):593-599. PubMed ID: 32336167
[TBL] [Abstract][Full Text] [Related]
17. Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention.
Vanitallie TB
Metabolism; 2013 Jan; 62 Suppl 1():S30-3. PubMed ID: 23021038
[TBL] [Abstract][Full Text] [Related]
18. Statistical issues on the diagnostic multivariate index assay for targeted clinical trials.
Liu JP; Chow SC
J Biopharm Stat; 2008; 18(1):167-82. PubMed ID: 18161547
[TBL] [Abstract][Full Text] [Related]
19. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.
Luo D; Smith JA; Meadows NA; Schuh A; Manescu KE; Bure K; Davies B; Horne R; Kope M; DiGiusto DL; Brindley DA
Front Genet; 2015; 6():357. PubMed ID: 26858745
[TBL] [Abstract][Full Text] [Related]
20. A visualization method measuring the performance of biomarkers for guiding treatment decisions.
Yang H; Tang R; Hale M; Huang J
Pharm Stat; 2016; 15(2):152-64. PubMed ID: 26632104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
